Zhi Jiang Biological (688317.SH): Cumulative spending of 22.73 million yuan to repurchase 0.74% of shares.

On June 4th, Gelon Hui reported that Zhejiang Hisun Pharmaceutical Co., Ltd. (688317.SH) had accumulated repurchased 1,442,987 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding trading as of May 31, 2024. The proportion of repurchased shares accounted for 0.74% of the company's total share capital of 194,704,350 shares. The highest and lowest transaction prices for the repurchase were 17.29 yuan/share and 13.79 yuan/share, respectively, with a total payment of RMB 22,732,140.99 yuan (exclusive of stamp duty, transaction fees, and other expenses).

Gelonghui FinanceJun 4 04:38 ET

Zhijiang Biotech (688317.SH): 3 products obtained relevant certification from the Food and Drug Administration of Thailand

Zhitong Finance App News, Zhijiang Biotech (688317.SH) announced that the company recently obtained relevant certification from the Food and Drug Administration of Thailand. The product names are High-Risk Human Papillomavirus (HPV) and Genotyping 16&18 Diagnostic Kit (PCR-fluorescence) high-risk human papillomavirus (HPV) nucleic acid testing and 16/18 typing kit (fluorescence PCR method), High-risk Hum

Zhitong FinanceMay 21 05:38 ET

Zhijiang Biotech (688317.SH): cumulative repurchase of 0.61% of shares

Gelonghui, May 7, 丨 Zhijiang Biotech (688317.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,184,853 shares through the Shanghai Stock Exchange trading system, accounting for 0.61% of the company's total share capital of 194,704,350 shares. The highest price of the repurchase transaction was 17.29 yuan/share, the lowest price was 13.79 yuan/share, and the total amount of capital paid was RMB 18,719,512.99 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceMay 7 05:37 ET

Zhijiang Biotech (688317.SH) reported first-quarter results, net profit of 26.90.69 million yuan, an increase of 346.47% over the previous year

According to Zhitong Finance App News, Zhijiang Biotech (688317.SH) released its report for the first quarter of 2024, achieving revenue of 52.273 million yuan, a year-on-year decrease of 39.27%. Achieved net profit attributable to shareholders of listed companies of 26.90.69 million yuan, an increase of 346.47% over the previous year. Achieved net profit of 258.17,300 yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 267.98% over the previous year.

Zhitong FinanceApr 28 04:50 ET

Zhijiang Biotech (688317.SH) reported 2023 annual results, with a net loss of 137 million yuan, changing from profit to loss over the previous year

Zhijiang Biotech (688317.SH) released its 2023 annual report. The company achieved operating income of 2 during the reporting period...

Zhitong FinanceApr 21 03:43 ET

Zhijiang Biotech (688317.SH): A total of 762,400 shares have been repurchased as of March 31

Gelonghui, April 2, 丨 Zhijiang Biotech (688317.SH) announced that as of March 31, 2024, the company had repurchased 762,357 shares of the company's shares through centralized bidding transactions, accounting for 0.39% of the company's total share capital of 194,704,350 shares. The highest price of the repurchase transaction was 17.29 yuan/share, the lowest price was 15.47 yuan/share, and the total amount of capital paid was RMB 12,370,042.82 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceApr 2 04:22 ET